C-Ring Oxidized Estrone Acetate Derivatives: Assessment of Antiproliferative Activities and Docking Studies

C-Ring oxidized estrone acetate derivatives as antiproliferative agents were prepared and tested against five cancer cell lines by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Flow cytometry assays to evaluate cell viability and modifications in cell cycle phases and molecular docking research against estrogen receptor proportional to, steroid sulfatase, and 17 beta-hydroxysteroid dehydrogenase type 1 were performed. 9 proportional to-Hydroxy,11 beta-nitrooxyestrone acetate was the most cytotoxic molecule against hormone-dependent cancer cells. Furthermore, flow cytometry experiments revealed that this 9 proportional to-hydroxy,11 beta-nitrooxy derivative markedly reduced HepaRG cells viability (similar to 92%) after 24 h of treatment. However, 9 proportional to-hydroxyestrone acetate led to selective inhibition of HepaRG cells growth, inducing a G(0)/G(1) cycle arrest, and did not originate a proliferation effect on T47-D cancer cells. Docking studies estimated a generally lower affinity of these compounds to estrogen receptor oc than predicted for estrone and 17 beta-estradiol. Therefore, this structural modification can be of interest to develop new anticancer estrane derivatives devoid of estrogenic action.